With its lead CAR-T flash­ing some PhI da­ta, Ar­cel­lx read­ies a jump to Nas­daq

Near­ly a year af­ter un­veil­ing a megaround Se­ries C, Ar­cel­lx is head­ed to­ward Nas­daq.

The Gaithers­burg, MD-based biotech pen­ciled in a $100 mil­lion IPO raise …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER